Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C

NCT01900002 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01900002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01900002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
September 13, 2013
Completion date
December 10, 2020
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adult hepatocellular carcinoma, bclc stage c hepatocellular carcinoma, recurrent adult hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v7, stage iiia hepatocellular carcinoma ajcc v7, stage iiib hepatocellular carcinoma ajcc v7, stage iiic hepatocellular carcinoma ajcc v7, stage iv hepatocellular carcinoma ajcc v7, stage iva hepatocellular carcinoma ajcc v7, stage ivb hepatocellular carcinoma ajcc v7, unresectable hepatocellular carcinoma